Core Viewpoint - Idorsia Ltd is proposing three candidates for election to its Board of Directors at the upcoming Annual General Meeting, aiming to enhance the Board's expertise in biopharmaceutical innovation and strategic execution [1][4][12]. Group 1: Board Composition - The nominees include Natalia Misciattelli and Gabriel Baertschi as independent members, and André C. Muller as a non-independent member [2][3]. - The proposed Board composition aims to strengthen the company with leaders who have extensive experience in global operations and biopharmaceutical innovation [3][4]. Group 2: Nominee Backgrounds - **Natalia Misciattelli**: CEO of AAVantgarde Bio with over 25 years of experience in biotechnology, focusing on therapeutic platforms and corporate development [5][6]. - **Gabriel Baertschi**: CEO of Grünenthal with more than 20 years in the pharmaceutical industry, known for his expertise in commercial strategy and market expansion [7][8]. - **André C. Muller**: Former CEO of Idorsia, instrumental in the company's development since its inception, bringing deep knowledge of Idorsia's business and strategy [9][10]. Group 3: Re-election of Current Board Members - The Board will also propose the re-election of Jean-Paul Clozel as Chairman, along with independent members Mathieu Simon and Sandy Mahatme, while Bart Filius will not stand for re-election [11][13]. Group 4: Annual General Meeting Details - The Annual General Meeting is scheduled for May 6, 2026, where shareholders are encouraged to register their shares by April 27, 2026, to participate in the voting process [14].

Core Viewpoint - Idorsia Ltd is proposing three candidates for election to its Board of Directors at the upcoming Annual General Meeting, aiming to enhance the Board's expertise in biopharmaceutical innovation and strategic execution [1][12]. Board Composition - The nominees include Natalia Misciattelli and Gabriel Baertschi as independent members, and André C. Muller as a non-independent member [2]. - The proposed Board composition aims to strengthen leadership with extensive experience in global operations and biopharmaceutical innovation, ensuring continuity through deep company knowledge [3]. Candidate Profiles - **Natalia Misciattelli**: CEO of AAVantgarde Bio with over 25 years of experience in biotechnology, focusing on therapeutic platforms and corporate development [5][6]. - **Gabriel Baertschi**: CEO of Grünenthal with more than 20 years in the pharmaceutical industry, known for his expertise in commercial strategy and market expansion [7][8]. - **André C. Muller**: Former CEO of Idorsia, who has been integral to the company's development since its inception, bringing extensive knowledge of Idorsia's business and strategic direction [9][10]. Re-election of Current Board Members - The Board will also propose the re-election of Jean-Paul Clozel as Chairman, along with independent members Mathieu Simon and Sandy Mahatme, while Bart Filius will not stand for re-election [11][13]. Annual General Meeting Details - The Annual General Meeting is scheduled for May 6, 2026, where shareholders are encouraged to register their shares by April 27, 2026, to participate in the voting process [14].

Core Viewpoint - Idorsia Ltd announces the resignation of Dr. Srishti Gupta as CEO and Board member, with the Board initiating a search for her successor while Jean-Paul Clozel will serve as interim CEO [1][2][4]. Group 1: Leadership Changes - Dr. Srishti Gupta has mutually agreed to step down from her role as CEO and from the Board of Directors [1]. - The Board has begun the process of finding a new CEO with extensive pharmaceutical leadership experience [4]. - Jean-Paul Clozel, the Chairman of the Board, will take over day-to-day operations as interim CEO until a successor is appointed [2][4]. Group 2: Acknowledgments and Future Outlook - Jean-Paul Clozel expressed gratitude for Dr. Gupta's significant contributions during her tenure, highlighting her commitment to the company's mission [3]. - Dr. Gupta reflected on her honor in leading Idorsia and the achievements made in advancing patient care [3]. - The Board plans to propose new independent candidates for election at the upcoming Annual General Meeting (AGM) to bring fresh perspectives [4]. Group 3: Company Overview - Idorsia aims to discover, develop, and commercialize innovative medicines, positioning itself as a leading biopharmaceutical company with a strong scientific foundation [6]. - The company is headquartered near Basel, Switzerland, and has a dedicated team focused on drug discovery and development, including a promising pipeline and partnerships [7].

Core Viewpoint - Idorsia Ltd announces the resignation of Dr. Srishti Gupta as CEO and Board member, with the Board initiating a search for her successor while Jean-Paul Clozel will serve as interim CEO [1][2][4]. Group 1: Leadership Changes - Dr. Srishti Gupta has mutually agreed to step down from her role as CEO and from the Board of Directors [1]. - The Board has begun the process of finding a new CEO with extensive pharmaceutical leadership experience [4]. - Jean-Paul Clozel, the Chairman of the Board, will take on the responsibilities of day-to-day operations as interim CEO [2][4]. Group 2: Acknowledgments and Future Outlook - Jean-Paul Clozel expressed gratitude for Dr. Gupta's significant contributions during her tenure, highlighting her commitment to the company's mission [3]. - Dr. Gupta reflected on her honor in leading Idorsia and the achievements made in advancing patient care [3]. - The Board plans to propose new independent candidates for election at the upcoming Annual General Meeting (AGM) to bring fresh perspectives [4][5]. Group 3: Company Overview - Idorsia aims to discover, develop, and commercialize innovative medicines, positioning itself as a leading biopharmaceutical company with a strong scientific foundation [6]. - The company is headquartered near Basel, Switzerland, and has a dedicated team focused on drug discovery and development, including a promising pipeline and partnerships [7].

Core Insights - Idorsia Ltd has entered into an exclusive distribution and commercialization agreement with Pharmalink Drug Store L.L.C for QUVIVIQ™ (daridorexant) in the UAE, Kuwait, Qatar, Oman, and Bahrain [2][4] - QUVIVIQ is an innovative treatment for insomnia that aims to improve daytime functioning and treat insomnia as a 24-hour disorder [3][6] Company Overview - Idorsia is focused on discovering, developing, and commercializing transformative medicines, with a strong scientific core and a promising in-house development pipeline [16][17] - Pharmalink has over 30 years of experience in the Gulf region, operating more than 200 pharmacies and providing a wide range of medications [13][14] Product Details - QUVIVIQ is a dual orexin receptor antagonist that selectively targets the orexin system, promoting restorative sleep without broadly suppressing brain activity [6] - Clinical trials have shown that daridorexant significantly improves sleep onset, maintenance, and total sleep time, with a notable enhancement in daytime functioning at a 50 mg dose compared to placebo [7] Market Context - Insomnia is highly prevalent in the GCC region, creating a significant demand for effective treatments [4] - The collaboration with Pharmalink strengthens Idorsia's commitment to establishing QUVIVIQ as a global brand, complementing its existing partnerships in various regions [8]

Core Insights - Idorsia Ltd announces the presentation of long-term results from the lucerastat treatment at the 22nd Annual WORLDSymposium™, highlighting its potential as a first-in-class oral substrate reduction therapy for Fabry disease [1][7] Study Overview - The MODIFY study was a multicenter, double-blind, randomized, placebo-controlled trial involving 118 patients to assess the efficacy and safety of lucerastat as an oral monotherapy for Fabry disease [3] - The study did not meet its primary endpoint of reducing neuropathic pain but showed significant reductions in plasma and urinary Gb3 levels compared to placebo, sustained over time in the open-label extension [4][14] Long-term Efficacy - An interim analysis of the open-label extension revealed a notable reduction in the rate of eGFR decline among patients treated with lucerastat, suggesting a potential disease-modifying effect [5] - Patients with impaired renal function at baseline experienced a marked attenuation of kidney function loss, indicating lucerastat's promise in long-term organ protection [5][14] Kidney Biopsy Sub-study - A kidney biopsy sub-study evaluated Gb3 accumulation in key kidney cell types in male patients with classic Fabry disease who received lucerastat for at least two years, providing insights into its impact on renal disease biology [2] Patient Population and Disease Background - Fabry disease is a rare, X-linked lysosomal storage disorder caused by mutations in the GLA gene, leading to the accumulation of Gb3 and progressive damage across multiple organ systems [6][8] - Recent studies suggest a higher prevalence of Fabry disease than previously estimated, with over 21,000 diagnosed patients expected across the US, EU5, and Japan by 2034 [9] Current Treatment Landscape - Current treatment options for Fabry disease include enzyme replacement therapies and oral chaperone therapy, which have limitations, highlighting the unmet need for a well-tolerated, oral, disease-modifying therapy [10][11]

Core Viewpoint - Idorsia Ltd has entered into an exclusive license and supply agreement with EMS S.A. to commercialize QUVIVIQ™ (daridorexant) in Latin America, marking a significant step in the company's global expansion strategy [2][3]. Company Overview - Idorsia Ltd is focused on developing transformative medicines and aims to challenge existing medical paradigms [15][16]. - EMS S.A. is Brazil's largest privately-owned pharmaceutical company, with over 60 years of history and a strong market presence [13][14]. Product Information - QUVIVIQ is an innovative treatment for insomnia that selectively blocks orexin receptors, promoting restorative sleep without broadly suppressing brain activity [5][6]. - Clinical trials have shown that daridorexant significantly improves sleep onset, maintenance, and daytime functioning compared to placebo [6]. Market Potential - Insomnia affects millions in Latin America, with current treatments often leading to next-day drowsiness and dependence, indicating a clear unmet need for safer alternatives [4][11]. - The partnership with EMS is expected to enhance the availability of QUVIVIQ in Latin America, addressing the significant demand for effective insomnia treatments [3][7]. Financial Aspects - Idorsia is set to receive a total milestone compensation of USD 20 million for the execution of the agreement, along with supply prices and double-digit royalties on net sales in Brazil and Mexico [10].

Core Viewpoint - Idorsia Ltd is positioned for profitability and growth with two products entering the value-acceleration phase and a promising pipeline of innovative medicines [2][3] Highlights in 2025 - Idorsia achieved strong operational progress, including the global expansion of QUVIVIQ, which is on track to meet sales guidance of approximately CHF 130 million [7] - The company completed debt restructuring and secured new financing, extending its cash runway into 2028 [7] - Clinical validation for its synthetic glycan vaccine technology and initiation of a proof-of-concept trial with a CCR6 antagonist were also notable achievements [7] Areas of Focus in 2026 - The company aims to make QUVIVIQ the standard of care for insomnia and maximize the value of TRYVIO/JERAYGO for uncontrolled hypertension [3][7] - Plans include advancing lucerastat for Fabry Disease registration and progressing the Phase 2 proof-of-concept immunology portfolio [7] - Idorsia will continue to explore partnerships and new sales models for QUVIVIQ, as well as support potential descheduling in the US [7]

Core Insights - Idorsia Ltd has published results from the pivotal Phase 3 MODIFY study and its open-label extension, highlighting the potential of lucerastat as an oral substrate reduction therapy for Fabry disease, particularly in patients with renal impairment [1][3]. Study Overview - The MODIFY study was a multicenter, double-blind, randomized, placebo-controlled trial involving 118 patients, aimed at assessing the efficacy and safety of lucerastat as an oral monotherapy for adult patients with Fabry disease [2]. - The study's primary endpoint of reducing neuropathic pain over six months was not met; however, lucerastat showed significant reductions in plasma and urinary Gb3 levels compared to placebo, with sustained effects observed in the open-label extension [3][17]. Renal Function Insights - An interim analysis of the open-label extension indicated a notable improvement in renal function trajectory, with a reduced rate of eGFR decline in patients treated with lucerastat compared to their eGFR slope prior to enrollment [4][9]. - In patients with impaired renal function or fast-deteriorating eGFR at baseline, lucerastat was associated with a significant reduction in kidney function loss, suggesting a potential disease-modifying effect [4][17]. Long-term Treatment and Tolerability - The open-label extension has collected data from patients treated with lucerastat for over 42 months, with some receiving treatment for more than 6 years, demonstrating good tolerability and no serious treatment-related adverse events [5][8]. - A kidney biopsy sub-study was conducted to evaluate Gb3 inclusions in kidney cells of male participants with classic Fabry disease treated for over 3 years with lucerastat [5]. Future Directions - The company is collaborating with the US FDA to design a new Phase 3 program to ensure a regulatory pathway for lucerastat's approval [6][10]. - A post-trial access program is being established to ensure continuity of care for participants still receiving lucerastat at the study's closure [7].

Core Viewpoint - Idorsia Ltd has initiated a Phase 2 proof-of-concept trial for IDOR-1117-2520, an oral selective CCR6 receptor antagonist aimed at treating moderate-to-severe psoriasis, with potential implications for other autoimmune conditions associated with CCR6 and Th17 pathways [2][10]. Company Overview - Idorsia is focused on developing transformative medicines and aims to evolve into a leading biopharmaceutical company with a strong scientific foundation [13]. - The company is headquartered near Basel, Switzerland, and has a dedicated team covering all aspects of drug development [14]. Product Details - IDOR-1117-2520 is a first-in-class, oral small-molecule drug designed to block the CCL20-driven recruitment of pathogenic CCR6-expressing immune cells, showing efficacy comparable to existing IL-17 and IL-23 inhibitors in preclinical models [9]. - The drug is currently in a Phase 2 trial, with results expected in the first quarter of 2027 [6]. Clinical Trial Information - The Phase 2 trial is a multicenter, double-blind, randomized, placebo-controlled study involving approximately 30 participants, evaluating the efficacy and safety of two dosages of IDOR-1117-2520 over 12 weeks [6]. - Primary efficacy will be measured by the change in Psoriasis Area and Severity Index (PASI) score from baseline to Week 12 [6]. Mechanism of Action - The CCR6 antagonism targets a key receptor that directs pathogenic immune cells to inflamed tissues, potentially modulating inflammation without broad immunosuppression [8]. - The Th17 pathway, which is implicated in various autoimmune diseases, is a primary focus for IDOR-1117-2520, aligning with Idorsia's strategic goals [4][11].